Breaking News Instant updates and real-time market news.

VBLT

VBL Therapeutics

$1.35

0.04 (3.05%)

08:14
06/03/19
06/03
08:14
06/03/19
08:14

VBL Therapeutics presents final VB-111 trial results at ASCO

VBL Therapeutics announced the presentation of the final results from a Phase 1/2 clinical trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer at the American Society of Clinical Oncology, or ASCO, annual meeting. Data demonstrated a median overall survival, or OS, of 498 days in the VB-111 therapeutic-dose arm, versus 172.5 days in the low-dose arm. Overall, 58% of evaluable patients treated with the therapeutic dose of VB-111 had a GCIG CA-125 response. In comparison, in the AURELIA trial, the GCIG CA-125 response rate was 31.8% with bevacizumab and chemotherapy, and only 11.6% with chemotherapy alone. VB-111 activity signals were seen despite unfavorable prognostic characteristics. There was a trend for favorable survival in patients who had CA-125 decrease greater than 50% in the VB-111 therapeutic-dose arm implicating CA-125 as a valuable biomarker for response to VB-111. Post treatment fever was also associated with a signal for improved survival.

VBLT VBL Therapeutics
$1.35

0.04 (3.05%)

10/15/18
HCWC
10/15/18
UPGRADE
Target $3
HCWC
Buy
VBL Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth upgraded VBL Therapeutics to Buy with an unchanged price target of $3. The "unwarranted" valuation decline and clinical readout in 2019 bring "new opportunity," Ramakanth tells investors in a research note. The stock has fallen 46% since March 3 despite no negative news from the company, the analyst says. He believes VBL's "promising" pipeline developments over the last six months, the weakness in the stock price, and the major clinical readout expected in 2019 has "significantly increased" the company's value proposition.

TODAY'S FREE FLY STORIES

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

06:24
10/16/19
10/16
06:24
10/16/19
06:24
Syndicate
Rhythm Pharmaceuticals 8.11M share Spot Secondary priced at $18.50 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

06:23
10/16/19
10/16
06:23
10/16/19
06:23
Syndicate
ProQR Therapeutics 9.091M share Spot Secondary priced at $5.50 »

Citi and Evercore ISI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SSNLF

Samsung

$0.00

(0.00%)

06:23
10/16/19
10/16
06:23
10/16/19
06:23
Periodicals
Samsung places further EUV equipment orders, DigiTimes reports »

Samsung Electronics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

06:23
10/16/19
10/16
06:23
10/16/19
06:23
Syndicate
Rhythm Pharmaceuticals 8.108M share Spot Secondary priced at $18.50 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

06:22
10/16/19
10/16
06:22
10/16/19
06:22
Syndicate
Principia Biopharma 7.5M share Spot Secondary priced at $28.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

EURN

Euronav NV

$10.72

-0.605 (-5.34%)

06:21
10/16/19
10/16
06:21
10/16/19
06:21
Recommendations
Euronav NV analyst commentary  »

Euronav a good play on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$370.99

-2.05 (-0.55%)

, EADSY

Airbus

$0.00

(0.00%)

06:20
10/16/19
10/16
06:20
10/16/19
06:20
Periodicals
Entry date for Boeing's 777-8 depending on customer demand, Reuters reports »

The date of entry into…

BA

Boeing

$370.99

-2.05 (-0.55%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

XOG

Extraction Oil & Gas

$2.65

-0.05 (-1.85%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Downgrade
Extraction Oil & Gas rating change  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CNI

Canadian National

$86.78

0.38 (0.44%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Upgrade
Canadian National rating change  »

Canadian National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

INOV

Inovalon

$15.04

0.2 (1.35%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Initiation
Inovalon initiated  »

Citi starts Inovalon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAB

Wabtec

$67.83

1.185 (1.78%)

06:17
10/16/19
10/16
06:17
10/16/19
06:17
Initiation
Wabtec initiated  »

Wabtec initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

ADBE

Adobe

$279.40

1.61 (0.58%)

06:15
10/16/19
10/16
06:15
10/16/19
06:15
Downgrade
Adobe rating change  »

Citi downgrades Adobe to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 04

    Nov

PLMR

Palomar

$40.61

-0.26 (-0.64%)

06:13
10/16/19
10/16
06:13
10/16/19
06:13
Initiation
Palomar initiated  »

Palomar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXSM

Axsome Therapeutics

$20.65

2.42 (13.27%)

06:12
10/16/19
10/16
06:12
10/16/19
06:12
Initiation
Axsome Therapeutics initiated  »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNBR

Sleep Number

$46.69

0.48 (1.04%)

06:11
10/16/19
10/16
06:11
10/16/19
06:11
Recommendations
Sleep Number analyst commentary  »

Sleep Number price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$86.78

0.38 (0.44%)

06:11
10/16/19
10/16
06:11
10/16/19
06:11
Upgrade
Canadian National rating change  »

Canadian National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

PLMR

Palomar

$40.61

-0.26 (-0.64%)

06:10
10/16/19
10/16
06:10
10/16/19
06:10
Initiation
Palomar initiated  »

Palomar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$218.42

3.27 (1.52%)

06:08
10/16/19
10/16
06:08
10/16/19
06:08
Downgrade
Canadian Pacific rating change  »

Canadian Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

MCK

McKesson

$138.17

4.01 (2.99%)

, ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

06:08
10/16/19
10/16
06:08
10/16/19
06:08
Recommendations
McKesson, AmerisourceBergen, Cardinal Health analyst commentary  »

Barclays ups McKesson…

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

I

Intelsat

$26.09

1.09 (4.36%)

06:05
10/16/19
10/16
06:05
10/16/19
06:05
Hot Stocks
Intelsat and Marlink extend partnership for maritime broadband services »

Intelsat and Marlink have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.00

0.145 (5.09%)

06:03
10/16/19
10/16
06:03
10/16/19
06:03
Recommendations
Foamix analyst commentary  »

Barclays likes Foamix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

TWTR

Twitter

$40.26

0.5 (1.26%)

06:03
10/16/19
10/16
06:03
10/16/19
06:03
Hot Stocks
Twitter clarifies when it will enforce rules against world leaders »

Twitter said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MOH

Molina Healthcare

$117.37

4.885 (4.34%)

06:02
10/16/19
10/16
06:02
10/16/19
06:02
Hot Stocks
Molina Healthcare to acquire certain assets of YourCare Health Plan for $40M »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FBM

Foundation Building Materials

$17.55

0.11 (0.63%)

06:01
10/16/19
10/16
06:01
10/16/19
06:01
Upgrade
Foundation Building Materials rating change  »

Foundation Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBSH

Commerce Bancshares

$60.24

0.87 (1.47%)

06:00
10/16/19
10/16
06:00
10/16/19
06:00
Earnings
Commerce Bancshares reports Q3 EPS 98c, consensus 92c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.